BOARD OF DIRECTORS

Our Board consists of eight Directors, comprising four executive Directors, one non-executive Director and three independent non-executive Directors. Our Directors serve a term of three years and are eligible for re-election upon expiry of their respective term of office. The independent non-executive Directors shall not hold office for more than six consecutive years pursuant to the relevant PRC laws and regulations.

Our Board is responsible for, and has general powers for, the management and conduct of our business.

The following table sets forth key information regarding our Directors:

Name	Age	Position(s)	Date of appointment as Director	Date of joining our Group	Role and responsibilities	Relationship with other Directors and senior management
Dr. Zhang Lianglu (張良祿)	38	Executive Director, Chairman of our Board and general manager	January 28, 2015	January 28, 2015	Responsible for strategic planning and overall business development of our Group	None
Dr. Dong Lanlan (董蘭蘭)	38	Executive Director, R&D president, vice general manager of R&D and manufacturing	February 4, 2021	September 26, 2016	Responsible for overall business development, R&D strategy and activities of our Group	None
Mr. Wu Zhicheng (吳志誠)	50	Executive Director, chief information officer	February 4, 2021	April 1, 2019	Responsible for formulation and implementation of the information and digitalization strategy of our Group	None
Dr. Guo Hong (郭洪)	45	Executive Director, R&D deputy director	February 4, 2021	June 20, 2018	Responsible for our R&D project of Class I in vitro diagnostic reagents	None
Mr. Liao Si'an (廖思安)	31	Non-executive Director	July 9, 2025	July 9, 2025	Responsible for providing management and strategic advice to our Group	None
Mr. Hu Yi (胡藝)	44	Independent non-executive Director	August 26, 2025	August 26, 2025	Responsible for providing independent advice and judgement to our Board	None
Mr. Kwok King Yiu (郭敬堯)	42	Independent non-executive Director	August 26, 2025	August 26, 2025	Responsible for providing independent advice and judgement to our Board	None
Mr. Wu Si (吳思)	46	Independent non-executive Director	August 26, 2025	August 26, 2025	Responsible for providing independent advice and judgement to our Board	None

The following sets forth the biographies of our Directors.

Executive Directors

Dr. Zhang Lianglu (張良祿), aged 38, is our founder, chairman of the Board, executive Director and general manager. Dr. Zhang was appointed as Director and general manager on January 28, 2015, and was re-designated as executive Director on September 20, 2025, effective on the **[REDACTED]**. As our founder, Dr. Zhang established its strategic focus on "Early Cancer Detection" and established our overall business direction. Dr. Zhang built our core team and technical platforms. Dr. Zhang also founded the bioinformatics team that developed the iTBFinder platform.

Dr. Zhang has served in several membership roles in the medical field including as standing committee member of the Laboratory Medicine Professional Committee of the Chinese Association of the Integration of Traditional and Western Medicine* (中國中西醫結合學會檢驗醫學專業委員會腫瘤分子診斷專家委員會) from April 2019 to April 2022, member of the Gastric Cancer Marker Group of the Chinese Anti-Cancer Association* (中國抗癌協會腫瘤標記物專業委員會胃癌標誌物協作組) from June 2019 to June 2020, a director of Hubei Drug and Medical Device Clinical Evaluation Society* (湖北省藥物與醫療器械臨床評價學會理事) from July 2021 to July 2024, and the vice chairman of the Popular Science and Education Specialist Committee of Hubei Immunology Society* (湖北免疫學會科普與教學專業委員會會副主任委員) from July 2021 to July 2024. He has also been serving as youth member of Cancer Screening and Early Diagnosis Professional Committee of the Chinese Association of Preventive Medicine* (中華預防醫學會癌症篩查與早診專業委員會) since January 2025.

Dr. Zhang holds the professional title of senior engineer in the field of medical devices, having obtained the qualification certificate issued by the Hubei Provincial Department of Human Resources and Social Security in December 2019. He has received multiple honors, including "Hubei Youth Talents" (湖北省青年英才) in September 2017, "Hubei Yangtze River Scholar" (湖北長江學子) in July 2020, and "3551 Optics Valley Entrepreneurial Talent" (3551光谷創業人才) awarded by Wuhan East Lake New Technology Development Zone Management Committee (武漢東湖新技術開發區管理委員會) in October 2016. In recognition of his contributions, Dr. Zhang received the following honorary credentials: the excellence award in the Beijing Semi-finals of China Medical Devices Design & Entrepreneurship Competition In Vitro Diagnostics Category (中國醫療器械創新創業大賽北京複賽(體外診斷組)) in August 2019, the gold award in the 5th China International "Internet+" College Students Innovation and Entrepreneurship Competition (In Vitro Diagnostics (IVD) Project Start-up Category) (第五屆中國"互聯網+"大學生創新創業大賽) in October 2019, the second prize in the Semi-finals and the third prize in the Finals of China Medical Devices Design & Entrepreneurship Competition (中國醫療器械創新創業大賽體外診斷(IVD)產品初創組) in September 2020, and on behalf of our Company, the First Prize in Invention and Entrepreneurship Award – Achievement Award by China Invention Association (中國發明協會) in October 2022.

Outside the medical field, Dr. Zhang also holds positions in various bodies, including standing council member of Hubei Youth Entrepreneurs Association (湖北青年企業家協會) since 2022, vice president of Hubei Shandong Chamber of Commerce (湖北山東商會) since September 2024, standing council member of Chushang Federation of Hubei Province (湖北省楚商聯合會) since May 2022, executive vice president of Wuhan University Economics and Management Branch (武漢大學經管分會) since July 2022, council member of Wuhan University Entrepreneurs Alumni Association (武漢大學校友企業家聯誼會) since March 2023, and president of the central China branch society alumni association of Bioinnovation Academy (貝殼學社校友會華中分會) since June 2023.

Dr. Zhang obtained a bachelor's degree in biological engineering and a master's degree in pathology and pathophysiology from Wuhan University (武漢大學) in the PRC in September 2010 and June 2013, respectively. Dr. Zhang further obtained a doctorate degree in cell biology from the College of Life Sciences, Wuhan University in the PRC in June 2022.

Dr. Dong Lanlan (董蘭蘭), aged 38, joined our Group in September 2016 and has served as a Director since February 2021. Dr. Dong was re-designated as our executive Director on September 20, 2025, effective on the **[REDACTED]**. Within our Group, Dr. Dong has also served as the R&D president since September 2016, where she is primarily responsible for overseeing the overall R&D strategy and activities of our Group and led the establishment and continuous improvement of the R&D system and directed the successful development of our Core Products, as well as supporting reagents such as sample preservation and methylation-conversion solutions. Dr. Dong has advanced our technological capabilities by integrating biomarker screening with algorithmic analysis and introducing micro-enrichment technology. Since March 2022, Dr. Dong has been serving as the vice general manager of our Group. Dr. Dong is responsible for the overall business development, R&D strategy and activities of our Group. Dr. Dong oversees R&D, production, quality, procurement, and warehousing, ensuring an efficient transition from research to production and the reliable delivery of marketed products. Dr. Dong also manages our quality-management system to ensure full compliance across the product lifecycle.

Dr. Dong holds the professional title of senior engineer in the field of medical devices, having obtained the qualification certificate issued by the Hubei Provincial Department of Human Resources and Social Security in April 2020. She has received multiple academic honors, including the First Prize in Invention and Entrepreneurship Award – Achievement Award by China Association of Inventions (中國發明協會) in October 2022, a certificate of honor in the National Disruptive Technology Innovation Competition (全國顛覆性技術創新大賽) in September 2024, and "3551 Optics Valley Entrepreneurial Talent" (3551光谷創業人才) from Wuhan East Lake New Technology Development Zone Management Committee (武漢東湖新技術開發區管理委員會) in December 2018.

Dr. Dong obtained a bachelor's degree in biological engineering from Wuhan Institute of Technology (武漢工程大學) in the PRC in June 2010. She further obtained a doctorate degree in immunology from the School of Basic Medical Sciences, Wuhan University (武漢大學) in the PRC in June 2015.

Mr. Wu Zhicheng (吳志誠), aged 50, joined our Group in April 2019 and has since served as the chief information officer of our Group. Mr. Wu has served as a Director since February 2021, and was re-designated as our executive Director on September 20, 2025, effective on the **[REDACTED]**. Mr. Wu is primarily responsible for the formulation and implementation of the information and digitalization strategy of our Group. As Chief Innovation Officer, Mr. Wu is responsible for the enhancement of our bioinformatics capabilities, the commercialisation of biomarkers derived from iTBFinder, and improvements in R&D efficiency.

Prior to joining our Group, Mr. Wu successively served as a lecturer and an associate professor at Jingdezhen Ceramic University (景德鎮陶瓷大學) in the PRC from July 2004 to October 2017. From November 2017 to March 2019, Mr. Wu served as a research assistant at Zhejiang Westlake University (西湖大學) in the PRC. At Westlake University, he contributed to international research projects on breast and thyroid cancers and developed a widely recognised multi-label algorithm.

Mr. Wu has been a certified associate professor since in December 2012. Mr. Wu obtained a bachelor's degree in water conservancy and hydropower engineering from Sichuan University (四川大學) in the PRC in July 1999. Mr. Wu further obtained a master's degree in computer software and theory from Sichuan University in June 2004. Mr. Wu has over 15 years of experience in bioinformatics research and teaching. He has received multiple provincial science and technology awards in Jiangxi Province and published more than 10 SCI-indexed papers with over 2,000 citations.

Dr. Guo Hong (郭洪), aged 45, joined our Group in June 2018 and has served as a R&D deputy director and Director since February 2021. Dr. Guo was re-designated as our executive Director on September 20, 2025, effective on the **[REDACTED]**. Dr. Guo is the responsible person for our R&D project of Class I in vitro diagnostic reagents. Under her leadership, our R&D team has developed and registered 14 Class I IVD products, including reagents for sample preservation, nucleic acid extraction, and methylation conversion. Dr. Guo also led the development of a one step extraction and conversion method that simplified operations and improved testing efficiency and automation compatibility, providing strong technical support for our Class III IVD products.

As our R&D Deputy Director, Dr. Guo manages Class I IVD projects, new-product development, and product enhancement. Working closely with Dr. Dong, she helps formulate R&D strategies, oversee project execution, and support team management and talent development.

Prior to joining our Group, Dr. Guo was an assistant research fellow at Wuhan Institute of Virology, Chinese Academy of Sciences (中國科學院武漢病毒研究所), where she was in molecular virology and viral immunology group from January 2009 to February 2011, and in double-stranded RNA virus molecular biology group from June 2011 to June 2018.

Dr. Guo obtained a bachelor's degree in biotechnology from College of Life Science and Technology, Huazhong Agricultural University (華中農業大學) in the PRC in June 2004. She further obtained her doctorate degree in animal genetics, breeding and reproduction from Huazhong Agricultural University in the PRC in December 2008.

Non-executive Directors

Mr. Liao Si'an (廖思安), aged 31, joined our Group in July 2025 and has since served as a non-executive Director. Mr. Liao is responsible for providing management and strategic advice to our Group.

In addition to his role in our Group, since February 2024, Mr. Liao has been serving as a senior vice president of investments at Guangzhou Jinyuan Kuntong Equity Investment Management Co., Ltd. (廣州金垣坤通股權投資管理有限公司), a company principally engaged in equity investment management, being primarily responsible for managing project investments.

Prior to joining our Group, Mr. Liao served as a scientist at GreenLight Bioscience (a company formerly listed on NASDAQ with ticker symbol: GRNA, principally engaged in bio-production of RNA solutions for agriculture) from June 2022 to June 2023, and as a scientist at ModeX Therapeutics (a subsidiary of OPKO Health, Inc., a company listed on NASDAQ with ticker symbol: OPK, principally engaged in medical testing diagnostics and pharmaceuticals) from July 2023 to January 2024.

Mr. Liao obtained the China Securities Investment Fund Industry Practitioner Certificate issued by the Asset Management Association of China (中國證券投資基金業協會) in November 2024. Mr. Liao obtained a bachelor's degree in chemistry and molecular engineering from Peking University (北京大學) in the PRC in June 2017. He further obtained a master's degree and doctorate degree in chemistry from Brown University in the United States in May 2019 and May 2022, respectively.

Independent Non-executive Directors

Mr. Hu Yi (胡藝), aged 44, is our independent non-executive Director. He is primarily responsible for providing independent advice and judgment to our Board and contributes his expertise to the Group's overseas expansion and strategic planning. He was appointed as our independent non-executive Director on August 26, 2025.

Since July 2007, Mr. Hu has been holding teaching positions at the School of Economics and Management, Wuhan University (武漢大學) in the PRC. Mr. Hu is currently an associate professor, being mainly responsible for teaching and supervising undergraduate, master and doctorate students studying majors in macroeconomics, microeconomics, international business and other related fields. In his teaching supervisory capacity, Mr. Hu is also responsible for conducting academic research, consulting and advisory work in the fields of macroeconomic situation and policies, corporate internationalization and transnational operations, industrial development trends and corporate strategic transformation. As the deputy head of the Department of World Economy of Wuhan University, Mr. Hu focuses on international economics, regional development and global business.

Mr. Hu obtained a bachelor's degree in international economics and trade from the School of Management, Xi'an Jiaotong University (西安交通大學) in the PRC in July 2001 and a master's degree in international trade from Wuhan University in June 2004. Mr. Hu further obtained a doctorate degree in international economics from Wuhan University (武漢大學) in June 2007.

Mr. Kwok King Yiu (郭敬堯), aged 42, is our independent non-executive Director. He is primarily responsible for providing independent advice and judgment to our Board. He was appointed as our independent non-executive Director on August 26, 2025.

Mr. Kwok is the founder of Kwok King Yiu CPA (Practising) (郭敬堯執業會計師), an audit firm principally engaged in providing audit services to SMEs. Mr. Kwok is also the founder of QDD Hong Kong Limited (企得得香港有限公司) (formerly known as GCC Corporate Services Limited), a company secretarial firm which is principally engaged in secretarial services ranging from company incorporation, bank account opening, bookkeeping to tax reporting services.

Mr. Kwok has accumulated almost 20 years of experience in financial accounting, investment banking compliance and listed company operations management. From September 2006 to September 2008, Mr. Kwok was a China tax specialist at KPMG China, where he was responsible for handling PRC tax compliance matters. Mr. Kwok served as a tax manager at RSM Hong Kong from June 2010 to May 2017, where he was responsible for providing consultancy services on Hong Kong and PRC tax compliance matters and international tax structures. From May 2017 to April 2019, Mr. Kwok worked as a compliance manager at BNP Paribas, being responsible for FATCA and CRS rule advisory work. From May 2019 to January 2024, Mr. Kwok was the chief financial officer and operations director of Shunho Investment Group Co., Ltd. (順灝投資集團有限公司), a company principally engaged in the manufacturing of new materials and eco-friendly packaging, where he was responsible for overall business operations management and making major decisions on mergers and acquisitions in Hong Kong.

Mr. Kwok obtained his bachelor's degree of business administration in finance and marketing from The Hong Kong University of Science and Technology (香港科技大學) in Hong Kong in November 2006. Mr. Kwok was accredited as a certified public accountant by the Hong Kong Institute of Certified Public Accountants (HKICPA) in September 2011.

Mr. Wu Si (吳思), aged 54, is our independent non-executive Director. He specializes in marketing strategies, business models and brand management and is primarily responsible for providing independent advice and judgment regarding the Group's marketing and commercialization strategies to our Board. He was appointed as our independent non-executive Director on August 26, 2025.

From August 1991 to March 2000, Mr. Wu served multiple roles including as technician and deputy instructor of the Chinese People's Armed Police Force Hubei Provincial Brigade* (中國人民武裝員警部隊湖北省), being responsible for local provincial security. Since July 2002, Mr. Wu has been holding various academic positions at Wuhan University (武漢大學) in the

PRC, where he successively served as lecturer, associate professor and professor (since July 2021) at the School of Economics and Management, Wuhan University. From May 2018 to May 2022, Mr. Wu also served as a director of the MBA Education Center of Wuhan University, where he was responsible for the overall direction, supervision and review of the MBA programme. Since July 2024, Mr. Wu has been serving as director of the EMBA Programme from the Department of Marketing and Tourism Management of Wuhan University, where in the latter role he was responsible for the overall direction, supervision and review of the EMBA programme.

Mr. Wu obtained a bachelor's degree in information systems engineering from The Chinese People's Armed Police Force Technical College (中國人民武裝員警部隊技術學院) in the PRC in July 1991, and a master's degree in computer software from Wuhan University in June 1998. Mr. Wu further obtained a doctorate degree in engineering (majoring in computer software and theory) from Wuhan University in June 2002. Mr. Wu obtained the qualification as a teacher in higher education granted by the Department of Education of Hubei Province (湖北省教育廳) in December 2011.

General

Save as disclosed in this section to this document, each of our Directors confirms that:

(a) he/she has obtained the legal advice referred to under Rule 3.09D of the Listing Rules on September 20, 2025, and understands the requirements under the Listing Rules that are applicable to him/her as a director of a listed issuer under the Listing Rules and the possible consequences of making a false declaration or giving false information to the Stock Exchange;

(b) he/she did not hold and has not held any other positions in our Group and any other members of our Group as of the Latest Practicable Date;

(c) he/she did not and has not been a director of any other publicly listed company during the three years prior to the Latest Practicable Date and as of the Latest Practicable Date;

(d) he/she did not have any relationship with any other Directors, senior management, substantial shareholders and controlling shareholders of our Company as of the Latest Practicable Date;

(e) he/she did not have any interest in a business which competes or is likely to compete, either directly or indirectly, with our Company's business which would require disclosure under Rule 8.10 of the Listing Rules as of the Latest Practicable Date;

(f) he/she has not completed his/her respective education programs as disclosed in this section by way of attendance of long distance learning or online courses; and

(g) to his/her best knowledge, information and belief, having made all reasonable inquiries, there were no other matter with respect to his/her appointment that needs to be brought to the attention of our Company, the Stock Exchange and the Shareholders and there were no information relating to him/her that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules as of the Latest Practicable Date.

Each of our independent non-executive Directors confirms:

(a) his/her independence after taking into consideration each of the factors referred to under Rules 3.13(1) to 3.13(8) of the Listing Rules;

(b) he/she did not have any past or present financial or other interest in the business of our Company or our subsidiaries, or any connection with any core connected person of our Company as of the Latest Practicable Date; and

there are no other factors which may affect his/her independence at the time of his/her appointment as our independent non-executive Director.

SENIOR MANAGEMENT

The following table sets forth the key information about our senior management:

Name	Age	Position(s)	Date of appointment as senior management	Date of joining our Group	Role and responsibilities	Relationship with other Directors and senior management
Dr. Zhang Lianglu (張良祿)	38	Executive Director, Chairman of our Board and general manager	January 28, 2015	January 28, 2015	Responsible for strategic planning and overall business development of our Group	None
Dr. Dong Lanlan (董蘭蘭)	38	Executive Director, R&D president, vice general manager of R&D and manufacturing	September 26, 2016	September 26, 2016	Responsible for overall business development, R&D strategy and activities of our Group	None
Mr. Wu Zhicheng (吳志誠)	50	Executive Director, chief information officer of our Group	April 1, 2019	April 1, 2019	Responsible for overall business development and maintenance of information systems of our Group	None
Mr. Xie Minghao (謝明昊) (alias 謝坤)	35	Chief financial officer, Board secretary and joint company secretary of our Group	April 10, 2025	April 10, 2025	Responsible for financial management planning, capital operations, listing, and investor relations of our Group	None
Ms. Zhou Dihan (周諦晗)	41	Chief technology officer and R&D deputy director	January 6, 2025	June 15, 2020	Responsible for technology R&D and product development, and overall technology strategic planning of our Group	None

Dr. Zhang Lianglu (張良祿), aged 38, is our founder, chairman of the Board, executive Director and general manager. For the biography of Dr. Zhang, please refer to "– Board of Directors – Executive Directors" in this section.

Dr. Dong Lanlan (董蘭蘭), aged 38, is our executive Director, R&D president and vice general manager of R&D and manufacturing. For the biography of Dr. Dong, please refer to "– Board of Directors – Executive Directors" in this section.

Mr. Wu Zhicheng (吳志誠), aged 50, is an executive Director and the chief information officer of our Group. For the biography of Mr. Wu, please refer to "– Board of Directors – Executive Directors" in this section.

Mr. Xie Minghao (謝明昊) (alias 謝坤), aged 35, joined our Group on April 10, 2025 and has served as the Board secretary of our Group since joining, as the chief financial officer of our Group since July 31, 2025 and as the joint company secretary of our Group since September 4, 2025. He is primarily responsible for financial management planning, capital operations, **[REDACTED]**, and investor relations of our Group.

Mr. Xie has accumulated relevant experience in the healthcare investment industry. From July 2016 to March 2017, he was a healthcare industry analyst in the investment department of CITIC Guoan (Tibet) Innovation Fund Management Co., Ltd. (中信國安(西藏)創新基金管理有限公司), a company principally engaged in management of funds specialising in the healthcare sector, where he was responsible for evaluating potential investments in funds. From April 2017 to May 2021, Mr. Xie successively served as senior analyst (healthcare industry) in the investment research department and as investment manager of the healthcare investment department of Guotai Junan Innovation Investment Co., Ltd. (國泰君安創新投資有限公司) (the parent company of which is listed on the Stock Exchange (2611.HK) and the Shanghai Stock Exchange (601211.SH), an investment management firm principally engaged in managing alternative assets of private equity, M&A funds and new infrastructure with an AUM of over RMB70 billion, where he was responsible for private equity investments in the healthcare industry. From May 2021 to August 2022, Mr. Xie was a senior investment manager of the financial development department of Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (正大天晴藥業集團股份有限公司) (the parent company of which is listed on the Stock Exchange (1177.HK)), a company principally engaged in R&D and manufacturing of liver drugs, where he was responsible for evaluating investment and divestment opportunities for the Company and the rendering of related investment advice.

From August 2022 to February 2025, Mr. Xie served as the board secretary of Jiangsu KeyGen BioTECH Corp., Ltd. (江蘇凱基生物技術股份有限公司) (listed on the NEEQ, stock code: 835272), a company principally engaged in R&D and manufacturing of biological reagents. Mr. Xie also obtained the Securities Practitioner Certificate (證券從業資格證書) in September 2011 and July 2015, and the Fund Practitioner Certificate (基金從業資格證書) and the Board Secretary Certificate (董事會秘書資格證書) awarded by the Shenzhen Stock Exchange, November 2016 and December 2024, respectively.

Mr. Xie obtained a bachelor's degree in accounting from Shanghai Lixin University of Accounting (上海立信會計學院) in the PRC (now known as Shanghai Lixin University of Accounting and Finance (上海立信會計金融學院) since the merger with Shanghai Finance Institution (上海金融學院)) in June 2013. He further obtained a master's degree in financial and organizational management from KEDGE Business School in France in May 2016.

Ms. Zhou Dihan (周諦晗), aged 41, joined our Group in June 2020, where she successively served as an R&D engineer and R&D deputy director of our Group (since September 21, 2020 until January 2025. Ms. Zhou was further appointed as our chief technology officer in January 2025. She is primarily responsible for technology R&D and product development (including R&D of Class III invitro diagnostic reagents and other product-related biotechnology research), and the overall technology strategic planning of our Group.

Prior to joining our Group, from January 2012 to July 2015, Ms. Zhou served as an assistant research fellow at Wuhan Institute of Virology, Chinese Academy of Sciences (中國科學院武漢病毒研究所), where she was responsible for conducting research studies on mucosal immunity. From August 2015 to May 2020, she engaged in postdoctoral research on biological sciences at Guangzhou Women and Children's Medical Center (廣州市婦女兒童醫療中心) and Wuhan Institute of Virology, Chinese Academy of Sciences.

Ms. Zhou holds the professional title of senior engineer in the field of medical devices, having obtained the qualification certificate issued by the Hubei Provincial Department of Human Resources and Social Security in December 2021. In addition, she was awarded the "Excellence Award" in the 4th Hubei High-value Patent Competition (第四屆湖北省高價值專利大賽優秀獎) in January 2025.

Ms. Zhou obtained a bachelor's degree in biology and a master's degree in microbiology from the College of Life Sciences, Wuhan University (武漢大學生命科學學院) in the PRC in June 2006 and June 2008, respectively. Ms. Zhou further obtained a doctorate degree in biochemistry and molecular biology from Wuhan Institute of Virology, Chinese Academy of Sciences (中國科學院武漢病毒研究所) in the PRC in July 2011.

General

Save as disclosed in this section, each of our senior management members confirms that:

(a) he/she did not hold and has not held any other positions in our Group and any other members of our Group as of the Latest Practicable Date;

(b) he/she did not have any relationship with any Directors, other members of senior management, substantial shareholders or controlling shareholders of our Company as of the Latest Practicable Date;

(c) he/she did not hold and has not held any other directorships in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the three years prior to the Latest Practicable Date and as of the Latest Practicable Date; and

(d) he/she has not completed his/her respective education programs as disclosed in this section by way of attendance of long distance learning or online courses.

JOINT COMPANY SECRETARIES

Mr. Xie was appointed as our joint company secretary on September 4, 2025. For the biographical details of Mr. Xie, please refer to "– Senior Management" in this section for details.

Ms. Pun Kim Ying (潘劍瑩), was appointed as our joint company secretary on September 4, 2025. Ms. Pun is currently serving as an assistant manager in the corporate secretarial department of SWCS Corporate Services Group (Hong Kong) Limited, a professional services provider specialising in corporate services, where she is mainly responsible for the company secretarial and compliance work for companies listed on the Stock Exchange. Ms. Pun has over 7 years of experience in the corporate secretarial field and has been providing corporate secretarial and compliance services to companies listed on the Stock Exchange and other listed company clients.

Ms. Pun has been an associate member of The Hong Kong Chartered Governance Institute (formerly known as "The Hong Kong Institute of Chartered Secretaries") and The Chartered Governance Institute (formerly known as "The Institute of Chartered Secretaries and Administrators") in United Kingdom since November 27, 2024.

COMPLIANCE ADVISOR

We have appointed WRise Capital Limited as our compliance advisor pursuant to Rule 3A.19 of the Listing Rules. Pursuant to Rule 3A.23 of the Listing Rules, the compliance advisor will advise us on the following circumstances:

- before the publication of any regulatory announcement, circular or financial report;

- where a transaction, which might be a notifiable or connected transaction, is contemplated including share issues, sales or transfers of treasury shares and share repurchases;
- where we propose to use the **[REDACTED]** of the **[REDACTED]** in a manner different from that detailed in this document or where our business activities, developments or results deviate from any forecast, estimate or other information in this document; and
- where the Stock Exchange makes an inquiry of us under Rule 13.10 of the Listing Rules.

Pursuant to Rule 3A.24 of the Listing Rules, WRise Capital Limited will, in a timely manner, inform us of any amendment or supplement to the Listing Rules and new or amended laws and regulations in Hong Kong applicable to us.

The terms of the appointment shall commence on the **[REDACTED]** and end on the date which we distribute our annual report of our financial results for the first full financial year commencing after the **[REDACTED]** and such appointment shall be subject to extension by mutual agreement.

BOARD COMMITTEES

We have established the following committees on our Board in accordance with the relevant PRC laws and regulations and the Corporate Governance Code as set out in the Appendix C1 to the Listing Rules (the "**Corporate Governance Code**"): an audit committee, a remuneration committee and a nomination committee. The committees operate in accordance with the terms of reference established by our Board.

Audit Committee

We have established an audit committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code. The Audit Committee consists of Mr. Kwok King Yiu, Mr. Hu Yi and Mr. Wu Si, with Mr. Kwok King Yiu being the chairperson of the committee. Mr. Kwok King Yiu holds the appropriate professional qualifications/the appropriate accounting or related financial management expertise as required under Rules 3.10(2) and 3.21 of the Listing Rules.

The primary duties of the Audit Committee are to assist our Board in providing an independent view of the effectiveness of our financial reporting process, internal control and risk management systems, overseeing the audit process, and performing other duties and responsibilities as assigned by our Board, which includes amongst other things:

- proposing to our Board the appointment and replacement of external auditors and monitoring the independence of external auditors and evaluating their performance;
- examining the financial reporting system, the risk management and internal control system of our Company, overseeing their rationality, efficiency and implementation and making recommendations to our Board;
- liaising between our internal audit department and external auditors;
- reviewing our financial information and related disclosures; and
- other duties conferred by our Board.

Remuneration Committee

We have established a remuneration committee with written terms of reference in compliance with Rule 3.25 of the Listing Rules and the Corporate Governance Code. The Remuneration Committee consists of Mr. Wu Si, Dr. Zhang Lianglu and Mr. Hu Yi, with Mr. Wu Si being the chairperson of the committee.

The primary duties of the Remuneration Committee are to develop remuneration policies of our Directors, evaluate the performance, make recommendations on the remuneration packages of our Directors and senior management and evaluate and make recommendations on employee benefits, which include amongst other things:

- making recommendations to our Board on the policy and structure for all Directors' and senior management remuneration and on the establishment of a formal and transparent procedure for developing remuneration policy;
- reviewing and approving the management's remuneration proposals with reference to our Board's corporate goals and objectives;
- making recommendations to our Board on the remuneration packages of individual executive Directors and senior management;
- making recommendations to our Board on the remuneration of non-executive Directors;
- considering salaries paid by comparable companies, time commitment and responsibilities and employment conditions elsewhere in our Group;
- reviewing and approving compensation payable to executive Directors and senior management for any loss or termination of office or appointment to ensure that it is consistent with contractual terms and is otherwise fair and not excessive;
- reviewing and approving compensation arrangements relating to dismissal or removal of Directors for misconduct to ensure that they are consistent with contractual terms and are otherwise reasonable and appropriate;
- ensuring that no Director or any of their associates is involved in deciding that Director's own remuneration;
- reviewing and/or approving matters relating to share schemes under Chapter 17 of the Listing Rules; and
- other duties conferred by our Board.

Nomination Committee

We have established a nomination committee with written terms of reference in compliance with Rule 3.27A and the Corporate Governance Code. The Nomination Committee consists of Mr. Hu Yi, Dr. Dong Lanlan and Mr. Kwok King Yiu, with Mr. Hu Yi being the chairperson of the committee.

The primary duties of the Nomination Committee are to make recommendations to our Board in relation to the appointment and removal of Directors which includes, amongst other things:

- reviewing the structure, size and composition (including the skills, knowledge and experience) of our Board at lease annually and making recommendations to our Board regarding any proposed changes to complement our corporate strategy;

- identifying individuals suitably qualified to become our Board members and select or make recommendations to our Board on the selection of individuals nominated for directorships;
- assessing the independence of independent non-executive Directors;
- making recommendations to our Board on the appointment or re-appointment of Directors and succession planning for Directors, in particular the chairman and the chief executive; and
- other duties conferred by our Board.

CORPORATE GOVERNANCE

Our Company is committed to achieving high standards of corporate governance with a view to safeguarding the interests of our Shareholders.

Pursuant to code provision C.2.1 of Part 2 of the Corporate Governance Code, companies listed on the Stock Exchange are expected to comply with, but may choose to deviate from the requirement that the responsibilities between the chairman and the general manager should be segregated and should not be performed by the same individual. We do not have a separate chairman and general manager, and Dr. Zhang currently performs these two roles. The Board believes that vesting the roles of both the chairman and general manager in the same person has the benefit of ensuring consistent leadership within our Group and enables more effective and efficient overall strategic planning for our Group. Our Board considers that the balance of power and authority for the present arrangement will not be impaired and this structure will enable our Company to make and implement decisions promptly and effectively. Our Board will continue to review and consider splitting the roles of the chairman of our Board and the general manager of our Company if and when it is appropriate taking into account the circumstances of our Group as a whole.

Our Directors recognize the importance of incorporating elements of good corporate governance in the management structures and internal control procedures of our Group to achieve effective accountability. Our Company intends to comply with the Corporate Governance Code set out in Appendix C1 of the Listing Rules and the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules after the **[REDACTED]**.

BOARD DIVERSITY

We seek to achieve board diversity through the consideration of a number of factors, including but not limited to gender, age, cultural and educational background, ethnicity, professional experience, skills, knowledge and length of service. We will adopt a board diversity policy (the "**Board Diversity Policy**") prior to the **[REDACTED]** to enhance the effectiveness of our Board and to maintain a high standard of corporate governance. Pursuant to the Board Diversity Policy, in reviewing and assessing suitable candidates to serve as a Director, the Nomination Committee will consider a range of diversity perspectives with reference to our Company's business model and specific needs, including but not limited to gender, age, language, cultural and educational background, professional qualifications, skills, knowledge, industry, regional experience and length of service. Furthermore, our Nomination Committee is responsible for reviewing the diversity of our Board, reviewing the Board Diversity Policy from time to time, developing and reviewing measurable objectives for implementing the Board Diversity Policy, and monitoring the progress on achieving these measurable objectives in order to ensure that the Board Diversity Policy remains effective.

Our Directors have a balanced mixed of knowledge and skills, including but not limited to banking, tax compliance, healthcare R&D and investment management. They obtained degrees in various majors including chemistry, animal genetics, computer systems, molecular biology, immunology and global economics. Furthermore, our Board has a relatively wide range of ages, ranging from 30 years old to 71 years old, and consists of seven male members and two female members. Our Company has reviewed the membership, structure and composition of our Board, and is of the opinion that the structure of our Board is reasonable, and the experience and skills of the Directors in various aspects and fields can enable our Company to maintain a high standard of operation.

Our Company will (i) disclose the biographical details of each Director and (ii) report on the implementation of the Board Diversity Policy (including whether we have achieved board diversity) in its annual corporate governance report. In particular, our Company will take opportunities to increase the proportion of female members of our Board when selecting and recommending suitable candidates for Board appointments to help enhance gender diversity in accordance with stakeholder expectations and recommended best practices. Our Company also intends to promote gender diversity when recruiting staff at the mid to senior level so that our Company will have a pipeline of female senior management and potential successors to our Board. We believe that such merit-based selection process with reference to our Board Diversity Policy and the nature of our business will be in the best interests of our Group and our Shareholders as a whole.

COMPENSATION OF DIRECTORS AND MANAGEMENT

We offer our executive Directors and senior management members, who are also employees of our Group, emolument in the form of salaries, bonuses, allowances and benefits in kind, performance related bonuses, share-based payment expenses and pension scheme contributions. Our Directors' remuneration is determined with reference to the relevant Director's experience and qualifications, level of responsibility, performance and the time devoted to our business, and the prevailing market conditions. Our independent non-executive Directors receive emolument based on their responsibilities (including being members or the chairperson of Board committees).

The aggregate amounts of remuneration (including salaries, discretionary bonuses, pension scheme contributions, housing funds, medical insurance, social insurance and other employee benefits) which were paid or payable to our Directors for the two financial years ended December 31, 2024 and 2025 were RMB2.24 million and RMB17.54 million, respectively.

It is estimated that the aggregate amount of remuneration (including salaries, discretionary bonuses, pension scheme contributions, housing funds, medical insurance, social insurance and other employee benefits) payable to our Directors for the financial year ending December 31, 2026 would be approximately RMB2.6 million under arrangements in force as of the date of this document.

For the two financial years ended December 31, 2024 and 2025, there were three and three Directors among the five highest paid individuals, respectively. The aggregate amounts of remuneration (including salaries, bonuses, allowances and benefits in kind, performance related bonuses, share-based payment expenses and pension scheme contributions) which were paid or payable by our Group to our five highest paid individuals (excluding Directors) for the two financial years ended December 31, 2024 and 2025 were RMB1.47 million and RMB2.53 million, respectively.

During the Track Record Period, (i) no remuneration was paid to our Directors or the five highest paid individuals as an inducement to join, or upon joining our Group, (ii) no compensation was paid to, or receivable by, our Directors, past Directors or the five highest paid individuals for the loss of office as a director of any member of our Group or any other office in connection with the management of the affairs of any member of our Group, and (iii) none of our Directors waived or agreed to waive any emoluments.

Except as disclosed above, no other payment has been paid, or is payable, by our Group to our Directors or the five highest paid individuals of our Group during the Track Record Period.

For additional information on Directors' remuneration during the Track Record Period as well as information on the five highest paid individuals, please refer to notes 7(b) and 31 to the Accountant's Report in Appendix I in this document.